Non-hormonal strategies for managing menopausal symptoms in cancer survivors: an update
- PMID: 31123492
- PMCID: PMC6445536
- DOI: 10.3332/ecancer.2019.909
Non-hormonal strategies for managing menopausal symptoms in cancer survivors: an update
Abstract
Vasomotor symptoms, particularly hot flushes (HFs), are the most frequently reported symptom by menopausal women. In particular, for young women diagnosed with breast cancer, who experience premature ovarian failure due to cancer treatments, severe HFs are an unsolved problem that strongly impacts on quality of life. The optimal management of HFs requires a personalised approach to identify the treatment with the best benefit/risk profile for each woman. Hormonal replacement therapy (HRT) is effective in managing HFs but it is contraindicated in women with previous hormone-dependent cancer. Moreover, many healthy women are reluctant to take HRT and prefer to manage symptoms with non-hormonal strategies. In this narrative review, we provide an update on the current available non-oestrogenic strategies for HFs management for women who cannot, or do not wish to, take oestrogens. Since isoflavones have oestrogenic properties and it is not known if they can be safely consumed by women with previous hormone-dependent cancer, they were excluded. Selective serotonin reuptake inhibitors/selective serotonin-norepinephrine reuptake inhibitors, as well as other neuroactive agents, some herbal remedies and behavioural strategies are considered.
Keywords: hot flushes; menopause; non-hormonal therapies; non-oestrogenic therapies; vasomotor symptoms.
Conflict of interest statement
Anna Maria Paoletti, Francesco De Seta and Stefano Lello declare no conflict of interests. Nicoletta Biglia had a financial relationship (lecturer, member of advisory boards and/or consultant) with Gedeon Richter, Shionogi Limited and Italfarmaco. Rossella E Nappi has a financial relationship (lecturer, member of advisory boards and/or consultant) with Bayer HealthCare, Endoceutics, Gedeon Richter, HRA Pharma, MSD, Novo Nordisk, Pfizer, Shionogi and Teva. Valentina E Bounous had a financial relationship with Italfarmaco S.p.A. (medical writing) and has a financial relationship with Shionogi (medical writing, tables preparation).
Similar articles
-
Nonpharmacological therapies for the management of menopausal vasomotor symptoms in breast cancer survivors.Support Care Cancer. 2021 Mar;29(3):1183-1193. doi: 10.1007/s00520-020-05754-w. Epub 2020 Sep 17. Support Care Cancer. 2021. PMID: 32940768 Review.
-
EMAS position statement: Non-hormonal management of menopausal vasomotor symptoms.Maturitas. 2015 Jul;81(3):410-3. doi: 10.1016/j.maturitas.2015.04.009. Epub 2015 Apr 22. Maturitas. 2015. PMID: 25982505 Review.
-
Managing menopausal symptoms after cancer.Climacteric. 2019 Dec;22(6):572-578. doi: 10.1080/13697137.2019.1646718. Epub 2019 Aug 21. Climacteric. 2019. PMID: 31433675 Review.
-
Treatment of climacteric symptoms in survivors of gynaecological cancer.Maturitas. 2015 Nov;82(3):296-8. doi: 10.1016/j.maturitas.2015.07.006. Epub 2015 Jul 22. Maturitas. 2015. PMID: 26341044 Review.
-
A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients.Springerplus. 2015 Feb 10;4:65. doi: 10.1186/s40064-015-0808-y. eCollection 2015. Springerplus. 2015. PMID: 25713759 Free PMC article.
Cited by
-
Effect of Serelys Homme on the Incidence and Severity of Vasomotor Symptoms and Quality-of-Life Impairments in Patients Receiving Hormone Therapy and Radiation for Localized Prostate Cancer: Results of the ESCULAPE Phase 2 Prospective Study.Adv Radiat Oncol. 2023 Apr 24;8(5):101255. doi: 10.1016/j.adro.2023.101255. eCollection 2023 Sep-Oct. Adv Radiat Oncol. 2023. PMID: 37408674 Free PMC article.
-
Exosome Therapy: A Novel Approach for Enhancing Estrogen Levels in Perimenopause.Int J Mol Sci. 2024 Jun 27;25(13):7075. doi: 10.3390/ijms25137075. Int J Mol Sci. 2024. PMID: 39000181 Free PMC article.
-
Nonhormonal Pharmacotherapies for the Treatment of Postmenopausal Vasomotor Symptoms.Cureus. 2024 Jan 17;16(1):e52467. doi: 10.7759/cureus.52467. eCollection 2024 Jan. Cureus. 2024. PMID: 38371081 Free PMC article. Review.
-
Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials.JAMA. 2024 Aug 22;332(16):1343-54. doi: 10.1001/jama.2024.14618. Online ahead of print. JAMA. 2024. PMID: 39172446 Free PMC article.
-
Insomnia in Postmenopausal Women: How to Approach and Treat It?J Clin Med. 2024 Jan 12;13(2):428. doi: 10.3390/jcm13020428. J Clin Med. 2024. PMID: 38256562 Free PMC article. Review.
References
-
- Blümel JE, Chedraui P, Baron G, et al. Collaborative group for research of the climacteric in Latin America (REDLINC), a large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women. Menopause. 2011;18:778–785. doi: 10.1097/gme.0b013e318207851d. - DOI - PubMed
-
- Avis NE, Crawford SL, Greendale G, et al. Study of women’s health across the nation (SWAN), study of women’s health across the nation, duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175:531–539. doi: 10.1001/jamainternmed.2014.8063. - DOI - PMC - PubMed
-
- Hunter M, Gentry-Maharaj A, Ryan A, et al. Prevalence, frequency and problem rating of hot flushes persist in older postmenopausal women: impact of age, body mass index, hysterectomy, hormone therapy use, lifestyle and mood in a cross-sectional cohort study of 10 418 British women aged 54–65: Prevalence, frequency and problem rating of hot flushes. BJOG. 2012;119:40–50. doi: 10.1111/j.1471-0528.2011.03166.x. - DOI - PubMed